The stock of Atara Biotherapeutics Inc. (NASDAQ:ATRA) increased by $0.29 on Wednesday to $1.87, up 18.37 percent. The last five days have seen an average of 1,207,317 shares of common stock traded. 14 times new highs were reached in the current year, with a fall of -$1.4250. The average number of shares traded over the last 20 days was 942,844, while the average volume over the last 50 days totaled 1,107,700.
ATRA stock appreciated 32.64% since last month. On 08/21/23, the company’s shares reached a one-month low of $1.2500. The stock touched a high of $5.64 on 02/06/23, after rallying from a low of $1.25 in 52 weeks. The price of ATRA stock has declined by -42.98% or -$1.4250 this year, reaching a new high 14 times. Still, the stock price is down -66.84% from the 52-week high.
Insider Transactions
ATRA stock investors should be aware that Atara Biotherapeutics Inc. (ATRA) stock had its last reported insider trading activity 35 days ago on Aug 16. On Aug 16, President and CEO Touchon Pascal sold 30,766 shares at $1.65 each. This transaction resulted in the insider making $50,835. On Aug 16, Nguyen AnhCo sold 15,126 shares at a price of US$1.65. After the transaction, the insider now owns 285,999 shares. EVP, Chief Legal Officer Murugan Amar had earlier sold 8,672 shares on Aug 16 for $1.65 a share. The transaction was completed for $14,330.
Valuation Metrics
Beta for the stock is 1.01. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 27.41, the price-to-book (PB) ratio of 26.72.
Financial Health
For the three months ended June 30, Atara Biotherapeutics Inc.’s quick ratio was 2.20, while its current ratio was 2.30, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 54.70% percent. Based on annual data, it had gross profit of $344.09 million and revenue of $63.57 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ATRA’s return on assets (ROA) during the last 12 months has been -94.20%. There was a -214.10% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -315.50%.
Earnings Surprise
According to Atara Biotherapeutics Inc.’s quarterly financial report for the quarter that ended June 30. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $3.61 million, while revenues fell by -1328.81% to $4.25 million. It was predicted that Atara Biotherapeutics Inc.’s quarterly earnings would be -$0.68, but it ended up being -$0.67, beating the consensus by -1.50%. EBITDA was -$70.97 million for the quarter. At the end of Atara Biotherapeutics Inc.’s most recent quarter ended June 30, its liabilities totaled 238.99 million, while its total debt was $64.71 million. Equity owned by shareholders amounts to $101.1 million.
Technical Picture
Here’s a quick look at Atara Biotherapeutics Inc.’s (ATRA) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 69.62%, suggesting the stock is Neutral, with a 105.26% historical volatility rate.
The stochastic %K and %D were 57.83% and 46.24% respectively, while the average true range (ATR) was 0.1471. Based on the 14-day stochastic reading of 80.18%, the RSI (14) reading is 60.35%. On the 9-day MACD Oscillator, the stock is at 0.0756, and the 14-day reading is at 0.0982.
Analyst Ratings
Atara Biotherapeutics Inc. (NASDAQ: ATRA) was downgraded by Citigroup to a a Sell rating in its latest research report. The stock was previously rated as a a Neutral. Analysts have assigned Atara Biotherapeutics Inc. (ATRA) an Overweight rating. ATRA is a stock that is recommended for selling by 2 brokerage firms, while 2 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 6 others recommend it as a buy.
What is ATRA’s price target for the next 12 months?
The current consensus forecast for the stock is between $1.40 and $31.00, with a median target price of $20.00. In analyzing these forecasts, the average price target given by analysts for Atara Biotherapeutics Inc. (ATRA) is $16.19.
